(3S,5S,10S,13R,14S)-3,5,14-trihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carboxaldehyde

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (3S,5S,10S,13R,14S)-3,5,14-trihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carboxaldehyde
• 英文别名: (3S,5S,10S,13R,14S)-3,5,14-trihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde
• 化学式: C₂₃H₃₂O₆
• 分子量: 404.5
• InChiKey: ODJLBQGVINUMMR-VJHNTTCYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy
  申请人：Meier Thomas

  公开号：US20070259837A1

  公开（公告）日：2007-11-08

  The invention relates to the therapeutic use of certain classes of steroid compounds for treatment of muscular diseases, in particular muscle diseases caused by mutations in the gene encoding for dystrophin (Duchenne Muscular Dystrophy, DMD, and Becker Muscular Dystrophy, BMD). The steroid compounds increase the levels of the dystrophin-related protein utrophin in cultured human muscle cells derived from donors affected with Duchenne Muscular Dystrophy.
• [EN] INHIBITION OF INTERACTION BETWEEN OCT4 AND MAPKAPK2 OR DNA-PKCS TO REGULATE C-MYC IN CANCER<br/>[FR] INHIBITION D'INTERACTION ENTRE L'OCT4 ET LA MAPKAPK2 OU L'ADN-PKCS POUR RÉGULER LE C-MYC EN PRÉSENCE D'UN CANCER
  申请人：UNIV TEXAS TECH SYSTEM

  公开号：WO2021026529A1

  公开（公告）日：2021-02-11

  Embodiments of the present disclosure pertain to methods of treating a cancer in a subject by administering to the subject a compound that inhibits interaction between octamer-binding transcription factor 4 (OCT4) and Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), OCT4 and DNA-dependent protein kinase catalytic subunit (DNA-PKcs), or combinations thereof. Additional embodiments of the present disclosure pertain to the compounds of the present disclosure. Further embodiments of the present disclosure pertain to methods of inhibiting interaction between OCT4 and MAPKAPK2 and/or OCT4 and DNA-PKcs by exposing protein complexes to the compounds of the present disclosure. Additional embodiments of the present disclosure pertain to methods of screening potential inhibitors of protein-protein interaction between a first protein and a second protein.